Assembly Biosciences' (ASMB) Buy Rating Reaffirmed at HC Wainwright

Key Points

• HC Wainwright reaffirmed a "buy" rating on Assembly Biosciences with a $50 price target, implying an ~82.7% upside, while the MarketBeat consensus is a "Moderate Buy" with an average target of $42.75.
• Assembly reported a surprising quarter—$2.48 EPS versus a consensus of ($0.51) and $42.47M revenue vs. $7.42M expected—yet the company still shows a negative net margin and analysts project a -0.93 EPS for the fiscal year.
• Analyst opinions are mixed (five buys, one hold, one sell), the stock opened at $27.37 with a market cap of about $435M, and institutional investors own roughly 19.9% of the shares.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $50.00 target price on the biopharmaceutical company's stock. HC Wainwright's price target suggests a potential upside of 82.68% from the stock's previous close.

Other equities analysts also recently issued research reports about the stock. Guggenheim increased their price target on shares of Assembly Biosciences from $39.00 to $43.00 and gave the stock a "buy" rating in a report on Monday, April 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Assembly Biosciences in a report on Monday, April 20th. Finally, Wall Street Zen upgraded shares of Assembly Biosciences from a "buy" rating to a "strong-buy" rating in a report on Sunday, March 29th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $42.75.

Assembly Biosciences Stock Performance

ASMB stock opened at $27.37 on Monday. The firm has a market cap of $434.99 million, a price-to-earnings ratio of -36.99 and a beta of 1.09. The firm has a 50-day simple moving average of $28.60 and a two-hundred day simple moving average of $30.52. Assembly Biosciences has a one year low of $11.64 and a one year high of $39.71.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last released its quarterly earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 EPS for the quarter, beating the consensus estimate of ($0.51) by $2.99. Assembly Biosciences had a negative net margin of 8.47% and a negative return on equity of 5.63%. The business had revenue of $42.47 million during the quarter, compared to analyst estimates of $7.42 million. As a group, equities analysts predict that Assembly Biosciences will post -0.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE lifted its holdings in Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 3,319 shares in the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Assembly Biosciences during the 4th quarter worth $147,000. Acadian Asset Management LLC increased its position in shares of Assembly Biosciences by 42.1% during the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company's stock worth $219,000 after purchasing an additional 6,823 shares during the last quarter. Charles Schwab Investment Management Inc. acquired a new stake in shares of Assembly Biosciences during the 4th quarter worth about $228,000. Finally, Virtus Investment Advisers LLC acquired a new stake in shares of Assembly Biosciences during the 4th quarter worth about $251,000. Hedge funds and other institutional investors own 19.92% of the company's stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc NASDAQ: ASMB is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company's core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly's research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company's lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.